- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00269373
Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors
February 20, 2012 updated by: Gedske Daugaard, Rigshospitalet, Denmark
PET-CT Scan as a Diagnostic Method in Unknown Primary Tumors
Is PET-CT scan better than PET or CT alone in diagnosing primary tumours in patients with unknown primary tumors?
Can information obtained with PET-CT replace other clinical and radiological investigations?
Is PET/CT cost-effective?
Study Overview
Detailed Description
Patients who fulfill the international definition of unknown primary tumors can be included, except:
- Young men (<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
- Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included.
- Women with adenocarcinoma in lymph nodes in the axilla will not be included.
Study Type
Observational
Enrollment (Actual)
136
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Rigshospitalet
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with unknown tumors
Description
Inclusion Criteria:
- Unknown primary tumors
Exclusion Criteria:
- Young men (<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
- Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included
- Women with adenocarcinoma in lymph nodes in the axilla will not be included
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gedske Daugaard, Rigshospitalet, Denmark
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2005
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
February 1, 2012
Study Registration Dates
First Submitted
December 22, 2005
First Submitted That Met QC Criteria
December 22, 2005
First Posted (Estimate)
December 23, 2005
Study Record Updates
Last Update Posted (Estimate)
February 22, 2012
Last Update Submitted That Met QC Criteria
February 20, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01 283694
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unknown Primary Tumor
-
M.D. Anderson Cancer CenterSanofi-SynthelaboCompletedUnknown Primary NeoplasmsUnited States
-
Apollomics (Australia) Pty. Ltd.Novotech (Australia) Pty Limited; Apollomics Inc. (formerly CBT Pharmaceuticals...CompletedSolid Tumor | Microsatellite Instability | Mismatch Repair Deficiency | Cancer of Unknown Primary SiteAustralia
-
Wei XuRecruitingChemotherapy Effect | Gene Mutation-Related Cancer | Tislelizumab | Cancer of Unknown Primary | Bone Cancer Metastatic | Immune Evasion, TumorChina
-
Fudan UniversityRecruiting
-
Rigshospitalet, DenmarkThe Novo Nordic FoundationCompletedUnknown Primary Cancer | Cancer of Unknown Primary Site | Unknown Primary, Squamous Cell CarcinomaDenmark
-
Fondazione del Piemonte per l'OncologiaCompleted
-
SCRI Development Innovations, LLCBiotheranostics, Inc.CompletedReview of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary CancerUnknown Primary CancerUnited States
-
Rigshospitalet, DenmarkWithdrawnUnknown Primary TumorsDenmark
-
Odense University HospitalUnknown
-
Sun Yat-sen UniversityThe First Affiliated Hospital of Anhui Medical University; Peking University... and other collaboratorsRecruiting
Clinical Trials on PET-CT
-
Peter MacCallum Cancer Centre, AustraliaMelbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...CompletedAcute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, AllogeneicAustralia
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
HALO DiagnosticsCompletedProstate CancerUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI)Completed
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm of Breast TNM Staging Distant Metastasis (M) | Untreated Bone MetastasesUnited States
-
The Catholic University of KoreaUnknownNon-small Cell Lung CancerKorea, Republic of
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruitingClear Cell Renal Cell CarcinomaChina